NCT07484022 2026-03-19
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Not yet recruiting
Generate Biomedicines
University of Iowa
Gruppo Oncologico Italiano di Ricerca Clinica
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pfizer